A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
·
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
OTHER
·

Directory Results for A phase 1 study of the bispecic anti-CD30/CD16A antibody construct to A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose ...

A phase 1 study of the bispecic anti-CD30/CD16A antibody construct
A Phase 1 Study To Evaluate The Safety, Tolerability ...
A Phase 1, Dose Escalation, Open-Label Clinical Trial with ...
A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose ...